We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cannabis Science Inc. Announces Progress in Bringing the First Cannabis Based Medicine to Market
News

Cannabis Science Inc. Announces Progress in Bringing the First Cannabis Based Medicine to Market

Cannabis Science Inc. Announces Progress in Bringing the First Cannabis Based Medicine to Market
News

Cannabis Science Inc. Announces Progress in Bringing the First Cannabis Based Medicine to Market

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cannabis Science Inc. Announces Progress in Bringing the First Cannabis Based Medicine to Market"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cannabis Science Inc. announces that it is finalizing agreements with suppliers, manufactures, and research institutions that it expects will close within days and weeks to come. Once these agreements are closed they will be announced along with details on how CBIS will bring its first Cannabis based pharmaceutical products to market.

“We have worked hard to get to this point and look forward to sharing the details with our shareholders in a timely fashion, and we appreciate their continued support.”

“We have worked hard to get to this point and look forward to sharing the details with our shareholders in a timely fashion, and we appreciate their continued support” stated Dr. Robert Melamede, President & CEO.

Cannabis Science is in negotiations with several companies in the US and internationally to contract or license its cannabis based formulations for development, certain rights to manufacturing processes, and sales in each prospective jurisdiction and or country.
Advertisement